Holly Pacenta

Clinical trials

• First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.

  Site PI · Recruiting · Phase 1

  Allterum Therapeutics, Inc

  2026–2028
• Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  Site PI · Recruiting · Phase 2

  National Cancer Institute (NCI)

  2025–2028
• Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

  Site PI · Recruiting · Phase 1

  St. Jude Children's Research Hospital

  2024–2027
• The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  Site PI · Recruiting · Phase 1, Phase 2

  PedAL BCU, LLC

  2022–2030